Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Int J Mol Sci. 2023 Apr 19;24(8):7508. doi: 10.3390/ijms24087508.
Neuroendocrine tumors (NEN) are a group of neoplasms that arise from hormonal and neural cells. Despite a common origin, their clinical symptoms and outcomes are varied. They are most commonly localized in the gastrointestinal tract. Targeted radioligand therapy (RLT) is a treatment option which has proven to be successful in recent studies. However, the possible outcomes and true safety profile of the treatment need to be fully determined, especially by new, more sensitive methods. Our study aimed to present an extended analysis of acute and chronic renal complications during and after radioligand therapy using, for the first time in the literature, innovative and complex renal parameters. Forty patients with neuroendocrine tumors underwent four courses of radioligand therapy with [Lu]Lu-DOTATATE or [Lu]Lu/[Y]Y-DOTATATE. Radioisotopes were administrated in intervals of 8-12 weeks, with concurrent intravenous nephroprotection. New detailed and sensitive renal parameters were used to determine the renal safety profile during and after radioisotope therapy for standard treatment of NEN. During the first and fourth courses of RLT, no change in the glomerular filtration rate (GFR) was observed. However, long-term observations one year after the treatment showed a 10% reduction in the GFR. During the first course of treatment, the fractional urea and calcium excretions increased, while the fractional potassium concentration decreased. The fractional calcium excretion remained highly increased in long-term observations. Decreases in urine IL-18, KIM-1 and albumin concentrations were observed during RLT. The concentrations of IL-18 and KIM-1 remained low even a year after therapy. The ultrasound parameters of renal perfusion changed during treatment, before partially returning to the baseline one year after therapy, and were correlated with the biochemical parameters of renal function. A permanent increase in diastolic blood pressure was correlated with the decrease in the GFR observed during the study. In this innovative and complex renal assessment during and after RLT, we found a permanent 10% per year decrease in the GFR and noticeable disturbances in renal tubule function. The diastolic blood pressure also increased.
神经内分泌肿瘤(NEN)是一组起源于激素和神经细胞的肿瘤。尽管它们具有共同的起源,但它们的临床症状和结果却各不相同。它们最常发生在胃肠道。靶向放射性配体治疗(RLT)是一种治疗选择,最近的研究已经证明它是成功的。然而,治疗的可能结果和真正的安全性概况需要通过新的、更敏感的方法来全面确定。我们的研究旨在使用文献中首次使用的创新和复杂的肾脏参数,对 RLT 期间和之后的急性和慢性肾脏并发症进行扩展分析。40 名神经内分泌肿瘤患者接受了[Lu]Lu-DOTATATE 或[Lu]Lu/[Y]Y-DOTATATE 四次 RLT 治疗。放射性同位素以 8-12 周的间隔给药,并同时进行静脉内肾脏保护。使用新的详细和敏感的肾脏参数来确定标准治疗 NEN 的 RLT 期间和之后的肾脏安全性概况。在 RLT 的第一和第四疗程中,肾小球滤过率(GFR)没有变化。然而,治疗一年后的长期观察显示 GFR 降低了 10%。在治疗的第一疗程中,尿素和钙的分数排泄增加,而钾的分数浓度降低。长期观察中,钙的分数排泄仍然高度增加。在 RLT 期间观察到尿液中 IL-18、KIM-1 和白蛋白浓度降低。即使在治疗一年后,IL-18 和 KIM-1 的浓度仍然很低。RLT 期间,肾脏灌注的超声参数发生变化,部分在治疗一年后恢复到基线,并且与肾功能的生化参数相关。在研究过程中观察到的舒张压永久性升高与研究期间观察到的 GFR 下降相关。在 RLT 期间和之后的这种创新和复杂的肾脏评估中,我们发现 GFR 每年永久性下降 10%,肾小管功能明显紊乱。舒张压也升高了。